Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety.
OBJECTIVE
The Canadian Rheumatology Association (CRA) has developed recommendations for the pharmacological management of rheumatoid arthritis (RA) with traditional and biologic disease-modifying antirheumatic drugs (DMARD) in 2 parts. Part II, focusing on specific safety aspects of treatment with traditional and biologic DMARD in patients with RA, is reported here.


METHODS
Key questions were identified a priori based on results of a national needs-assessment survey. A systematic review of all clinical practice guidelines and consensus statements regarding treatment with traditional and biologic DMARD in patients with RA published between January 2000 and June 2010 was performed in Medline, Embase, and CINAHL databases, and was supplemented with a "grey literature" search including relevant public health guidelines. Systematic reviews of postmarketing surveillance and RA registry studies were performed to update included guideline literature reviews as appropriate. Guideline quality was independently assessed by 2 reviewers. Guideline characteristics, recommendations, and supporting evidence from observational studies and randomized trials were synthesized into evidence tables. The working group voted on recommendations using a modified Delphi technique.


RESULTS
Thirteen recommendations addressing perioperative care, screening for latent tuberculosis infection prior to the initiation of biologic DMARD, optimal vaccination practices, and treatment of RA patients with active or a history of malignancy were developed for rheumatologists, other primary prescribers of RA drug therapies, and RA patients.


CONCLUSIONS
These recommendations were developed based on a synthesis of international RA and public health guidelines, supporting evidence, and expert consensus in the context of the Canadian health system. They are intended to help promote best practices and improve healthcare delivery for persons with RA.
The Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Mount Sinai Hospital, Toronto, Canada. claire.bombardier@utoronto.ca
Claire
C
Bombardier
Glen S
GS
Hazlewood
Pooneh
P
Akhavan
Orit
O
Schieir
Anne
A
Dooley
Boulos
B
Haraoui
Majed
M
Khraishi
Sharon A
SA
Leclercq
Jean
J
Légaré
Dianne P
DP
Mosher
James
J
Pencharz
Janet E
JE
Pope
John
J
Thomson
Carter
C
Thorne
Michel
M
Zummer
Michael A
MA
Gardam
Johan
J
Askling
Vivian
V
Bykerk
D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D032921:Consensus; D019317:Evidence-Based Medicine; D006801:Humans; D011358:Product Surveillance, Postmarketing
D018501:Antirheumatic Agents